Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III - 09/08/11
for the ENDEAVOR III Investigators
Résumé |
Background |
The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES) and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS).
Methods |
Data were obtained from the Endeavor Drug-Eluting Coronary Stent System Versus the Center Siromlimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR) III trial, a randomized study comparing ZES and SES for the treatment of de novo native coronary artery lesions. Serial (baseline and 8-month follow-up) IVUS was available in 258 patients (190 ZES, 68 SES).
Results |
At 8 months, ZES had greater percentage of neointimal volume index (ZES 1.1 ± 0.8 mm3/mm vs SES 0.2 ± 0.1 mm3/mm, P < .01), resulting in smaller lumen volume index (6.0 ± 2.0 mm3/mm vs 7.0 ± 2.1 mm3/mm, P < .05). Zotarolimus-eluting stents showed larger IVUS-detectable neointimal coverage over stent surface (50.2% vs 10.5%, P < .01) and greater mean neointimal thickness (0.19 ± 0.07 mm vs 0.10 ± 0.06 mm, P < .01). Zotarolimus-eluting stents had a significantly lower incidence of late-acquired incomplete stent apposition.
Conclusions |
Zotarolimus-eluting stent is associated with a significantly greater amount of neointimal hyperplasia compared with SES. This amount of hyperplasia in ZES is distributed throughout the stent at 8-month follow-up.
Le texte complet de cet article est disponible en PDF.Plan
| Drs. Miyazawa and Ako contributed equally to this work. |
|
| This study was supported by Medtronic Inc, Santa Rosa, CA. |
Vol 155 - N° 1
P. null - janvier 2008 Retour au numéro
Article précédent
- A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial
- Michele Gulizia, Salvatore Mangiameli, Serafino Orazi, Giacomo Chiarandà, Guglielmo Piccione, Nicolò Di Giovanni, Andrea Colletti, Orazio Pensabene, Francesco Lisi, Ludovico Vasquez, Andrea Grammatico, Giuseppe Boriani, on behalf of PITAGORA Study Investigators
- A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
- Ik-Kyung Jang, Neil J. Weissman, Michael H. Picard, Michael R. Zile, Veronica Pettigrew, Steven Shen, Jun Tatsuno, Mark G. Hibberd, Dan Tzivoni, Frans J. Th. Wackers, the EVOLVE Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?